A new method combining sequential immunoaffinity depletion and differential in gel electrophoresis to identify autoantibodies as cancer biomarkers

Journal of Immunological Methods

Volumn 396, Issue 1-2, 2013, Pages 23-32

  Grandjean, Marie ^a   Dieu, Marc ^b   Raes, Martine ^b   Feron, Olivier ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b University of Namur   (Belgium)

Author keywords

Autoantibodies; Glycolysis; Hypoxia; Serological proteome

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; ENZYME; EPITOPE; IMMUNOGLOBULIN G; PROTEIN; PROTEOME; TUMOR ANTIGEN; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CELL LYSATE; CONTROLLED STUDY; DIFFERENTIAL IN GEL ELECTROPHORESIS; GEL ELECTROPHORESIS; GLYCOLYSIS; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOGENICITY; IMMUNOLOGICAL PROCEDURES; INTERMETHOD COMPARISON; MALE; MOUSE; NEOPLASM; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN MODIFICATION; SEQUENTIAL IMMUNOAFFINITY DEPLETION; SEROLOGICAL PROTEOME ANALYSIS; TUMOR CELL;

AABS; AUTOANTIBODIES; GLYCOLYSIS; HYPOXIA; SEQUENTIAL IMMUNOAFFINITY DEPLETION-DIFFERENTIAL IN GEL ELECTROPHORESIS; SEROLOGICAL PROTEOME; SEROLOGICAL PROTEOME ANALYSIS; SERPA; SID-DIGE; TAA; TUMOR-ASSOCIATED ANTIGENS;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, NEOPLASM; AUTOANTIBODIES; CELL HYPOXIA; CELL LINE, TUMOR; CHROMATOGRAPHY, AFFINITY; COLORECTAL NEOPLASMS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EPITOPES; GLYCOLYSIS; HUMANS; IMMUNOGLOBULIN G; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROTEOME; TUMOR MARKERS, BIOLOGICAL;

MUS;

EID: 84884354170     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2013.07.006     Document Type: Article

References (25)

1. Apweiler R., Aslanidis C., Deufel T., Gerstner A., Hansen J., Hochstrasser D., Kellner R., Kubicek M., Lottspeich F., Maser E., Mewes H.W., Meyer H.E., Mullner S., Mutter W., Neumaier M., Nollau P., Nothwang H.G., Ponten F., Radbruch A., Reinert K., Rothe G., Stockinger H., Tarnok A., Taussig M.J., Thiel A., Thiery J., Ueffing M., Valet G., Vandekerckhove J., Verhuven W., Wagener C., Wagner O., Schmitz G. Approaching clinical proteomics: current state and future fields of application in fluid proteomics. Clin. Chem. Lab. Med. 2009, 47:724.
2. Bouzin C., Feron O. Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery. Drug Resist. Updat. 2007, 10:109.
3. Cho W.C. Contribution of oncoproteomics to cancer biomarker discovery. Mol. Cancer 2007, 6:25.
4. Daneau G., Boidot R., Martinive P., Feron O. Identification of cyclooxygenase-2 as a major actor of the transcriptomic adaptation of endothelial and tumor cells to cyclic hypoxia: effect on angiogenesis and metastases. Clin. Cancer Res. 2010, 16:410.
5. Defresne F., Bouzin C., Guilbaud C., Dieu M., Delaive E., Michiels C., Raes M., Feron O. Differential influence of anticancer treatments and angiogenesis on the seric titer of autoantibody used as tumor and metastasis biomarker. Neoplasia 2010, 12:562.
6. Desmetz C., Maudelonde T., Mange A., Solassol J. Identifying autoantibody signatures in cancer: a promising challenge. Expert. Rev. Proteomics 2009, 6:377.
7. Desmetz C., Mange A., Maudelonde T., Solassol J. Autoantibody signatures: progress and perspectives for early cancer detection. J. Cell Mol. Med. 2011, 15:2013.
8. Feron O. Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother. Oncol. 2009, 92:329.
9. Frerart F., Sonveaux P., Rath G., Smoos A., Meqor A., Charlier N., Jordan B.F., Saliez J., Noel A., Dessy C., Gallez B., Feron O. The acidic tumor microenvironment promotes the reconversion of nitrite into nitric oxide: towards a new and safe radiosensitizing strategy. Clin. Cancer Res. 2008, 14:2768.
10. Gunawardana C.G., Diamandis E.P. High throughput proteomic strategies for identifying tumour-associated antigens. Cancer Lett. 2007, 249:110.
11. Hanash S., Taguchi A. The grand challenge to decipher the cancer proteome. Nat. Rev. Cancer 2010, 10:652.
12. Hanash S.M., Pitteri S.J., Faca V.M. Mining the plasma proteome for cancer biomarkers. Nature 2008, 452:571.
13. Kim R., Emi M., Tanabe K., Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006, 66:5527.
14. Kulasingam V., Diamandis E.P. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat. Clin. Pract. Oncol. 2008, 5:588.
15. Lleo A., Invernizzi P., Gao B., Podda M., Gershwin M.E. Definition of human autoimmunity-autoantibodies versus autoimmune disease. Autoimmun. Rev. 2010, 9:A259-A266.
16. Ludwig N., Keller A., Leidinger P., Harz C., Backes C., Lenhof H.P., Meese E. Is there a general autoantibody signature for cancer?. Eur. J. Cancer 2012, 48:2451.
17. Mange A., Lacombe J., Bascoul-Mollevi C., Jarlier M., Lamy P.J., Rouanet P., Maudelonde T., Solassol J. Serum autoantibody signature of ductal carcinoma in situ progression to invasive breast cancer. Clin. Cancer Res. 2012, 18:1992.
18. Mathupala S.P., Ko Y.H., Pedersen P.L. Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 2006, 25:4777.
19. Petricoin E.F., Belluco C., Araujo R.P., Liotta L.A. The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat. Rev. Cancer 2006, 6:961.
20. Polet F., Feron O. Endothelial cell metabolism and tumour angiogenesis: glucose and glutamine as essential fuels and lactate as the driving force. J. Intern. Med. 2013, 273:156.
21. Reuschenbach M., von Knebel D.M., Wentzensen N. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol. Immunother. 2009, 58:1535.
22. Solassol J., Rouanet P., Lamy P.J., Allal C., Favre G., Maudelonde T., Mange A. Serum protein signature may improve detection of ductal carcinoma in situ of the breast. Oncogene 2010, 29:550.
23. Tan E.M., Zhang J. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol. Rev. 2008, 222:328.
24. Tan H.T., Low J., Lim S.G., Chung M.C. Serum autoantibodies as biomarkers for early cancer detection. FEBS J. 2009, 276:6880.
25. Vincent K.A., Feron O., Kelly R.A. Harnessing the response to tissue hypoxia: HIF-1 alpha and therapeutic angiogenesis. Trends Cardiovasc. Med. 2002, 12:362.